🫘 Diabetic Kidney Disease (DKD) Comprehensive Management
This tool frames multi-pillar management of diabetic kidney disease by eGFR and albuminuria, spanning RAAS inhibition, SGLT2 inhibitors, finerenone, glucose-lowering, and blood pressure, per KDIGO 2022.
Clinical takeaway
An SGLT2i is added for cardiorenal protection independent of glycemia, and a transient eGFR dip after starting is expected, not a reason to stop. (original synthesis · not guideline verbatim)
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to assemble the DKD regimen: RAAS blockade for albuminuria/hypertension, an SGLT2i at eGFR ≥ 20, finerenone for residual albuminuria, and statin/BP/lifestyle for all patients.
How it works
Pillars by eGFR/albuminuria: ACEi/ARB (albuminuria), SGLT2i (eGFR ≥ 20), finerenone (eGFR ≥ 25 + UACR ≥ 30 + normal K on RASi ± SGLT2i), metformin (eGFR ≥ 30) → GLP-1 RA, statin + BP < 130/80 for all.
Key points
- An SGLT2i is added for cardiorenal protection independent of glycemia, and a transient eGFR dip after starting is expected, not a reason to stop. (original synthesis · not guideline verbatim)
- Finerenone is added for residual albuminuria/risk on maximal RASi ± SGLT2i when potassium is normal, with potassium monitoring.
- Every DKD patient receives a statin, BP target < 130/80, and lifestyle measures, with periodic eGFR/UACR/potassium monitoring.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| eGFR | 45 mL/min/1.73m² |
|---|---|
| Albuminuria (UACR ≥ 30 mg/g) | Present |
→DKD comprehensive managementeGFR 45, with albuminuria
- RAAS inhibitor：ACEi or ARB to the maximum tolerated dose (first-line with comorbid hypertension and albuminuria); monitor creatinine and potassium after starting/adjusting
- SGLT2 inhibitor：For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected
- Finerenone：T2DM + eGFR ≥ 25 + UACR ≥ 30 + normal potassium, on a maximum tolerated ACEi/ARB (± SGLT2i) with residual albuminuria/risk: add the nonsteroidal MRA finerenone for cardiorenal benefit; monitor potassium
| eGFR | 45 mL/min/1.73m² |
|---|---|
| Albuminuria (UACR ≥ 30 mg/g) | Absent |
→DKD comprehensive managementeGFR 45, no albuminuria
- RAAS inhibitor：With comorbid hypertension, ACEi/ARB may be used; without albuminuria or hypertension, do not force use for renal protection
- SGLT2 inhibitor：For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected
- Glucose-lowering：Metformin first-line at eGFR ≥ 30; if metformin + SGLT2i still misses target or cardiovascular benefit/weight loss is needed, second-line GLP-1 RA; individualize HbA1c
Frequently asked questions
- What is Diabetic Kidney Disease (DKD) Comprehensive Management?
- This tool frames multi-pillar management of diabetic kidney disease by eGFR and albuminuria, spanning RAAS inhibition, SGLT2 inhibitors, finerenone, glucose-lowering, and blood pressure, per KDIGO 2022.
- How is Diabetic Kidney Disease (DKD) Comprehensive Management calculated? What is the core formula?
- Pillars by eGFR/albuminuria: ACEi/ARB (albuminuria), SGLT2i (eGFR ≥ 20), finerenone (eGFR ≥ 25 + UACR ≥ 30 + normal K on RASi ± SGLT2i), metformin (eGFR ≥ 30) → GLP-1 RA, statin + BP < 130/80 for all.
- When is Diabetic Kidney Disease (DKD) Comprehensive Management used?
- Use to assemble the DKD regimen: RAAS blockade for albuminuria/hypertension, an SGLT2i at eGFR ≥ 20, finerenone for residual albuminuria, and statin/BP/lifestyle for all patients.
- What are the key clinical points for Diabetic Kidney Disease (DKD) Comprehensive Management?
- An SGLT2i is added for cardiorenal protection independent of glycemia, and a transient eGFR dip after starting is expected, not a reason to stop. (original synthesis · not guideline verbatim) Finerenone is added for residual albuminuria/risk on maximal RASi ± SGLT2i when potassium is normal, with potassium monitoring. Every DKD patient receives a statin, BP target < 130/80, and lifestyle measures, with periodic eGFR/UACR/potassium monitoring.
- What are the limits and cautions when using Diabetic Kidney Disease (DKD) Comprehensive Management?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Diabetic Kidney Disease (DKD) Comprehensive Management calculated in practice? Can you show a worked example?
- Inputs: eGFR 45 mL/min/1.73m², Albuminuria (UACR ≥ 30 mg/g) Present → Result: DKD comprehensive management eGFR 45, with albuminuria（RAAS inhibitor: ACEi or ARB to the maximum tolerated dose (first-line with comorbid hypertension and albuminuria); monitor creatinine and potassium after starting/adjusting, SGLT2 inhibitor: For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected, Finerenone: T2DM + eGFR ≥ 25 + UACR ≥ 30 + normal potassium, on a maximum tolerated ACEi/ARB (± SGLT2i) with residual albuminuria/risk: add the nonsteroidal MRA finerenone for cardiorenal benefit; monitor potassium） Inputs: eGFR 45 mL/min/1.73m², Albuminuria (UACR ≥ 30 mg/g) Absent → Result: DKD comprehensive management eGFR 45, no albuminuria（RAAS inhibitor: With comorbid hypertension, ACEi/ARB may be used; without albuminuria or hypertension, do not force use for renal protection, SGLT2 inhibitor: For DKD with eGFR ≥ 20, add an SGLT2i (dapagliflozin/empagliflozin) for cardiorenal protection, independent of glycemia; continue to dialysis/transplant; a transient eGFR dip after starting is expected, Glucose-lowering: Metformin first-line at eGFR ≥ 30; if metformin + SGLT2i still misses target or cardiovascular benefit/weight loss is needed, second-line GLP-1 RA; individualize HbA1c）